RxSight, Inc.

NASDAQ:RXST

Medical - Devices

Healthcare
$5.01 +0.98%

+$0.05 today

Market cap
$210.07M
Beta
1.13
P/E (TTM)
-4.1
EPS (TTM)
-$1.13
52W Low $4.48High $14.29

Volume 0.74M

Average 0.80M

RXST Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

RxSight, Inc.NASDAQ: RXST

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $7.4M fell 22.7% year over year, ahead of the -43.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +4.4% a year.

Context

  • Cost of revenue amounted to 23.4% of revenue in FY2025, down 5.9 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -22.7% holds above the trailing-twelve-month pace of -43.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.4M+0.7% QoQ
Last fiscal yearDec 2025
$31.47M-23.2% YoY
LTMMar 2026
$29.3M-43.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.7%——
1 year-23.2%——
3-year CAGR+4.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
31.47M USD
Year-over-year change
-23.2%
4-year CAGR
+14.9%

Cost of Revenue vs competitors

How RXST compares with its peers on the latest reported figures

  • RXST's LTM Mar 2026 cost of revenue of $29.3M is the 6th highest of the 9 companies compared; the peer median is $47.16M.
  • Its year-over-year change of -43.5% is the lowest of 8, against a peer median of +13.4%.
  • Cost of revenue amounts to 23.0% of revenue for RXST, versus a peer median of 24.3%.
RXST Competitors Peer median
Cost of Revenue for RXST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CERSCerus CorporationLTM Mar 2026$101.8M +25.0%+8.5%45.7%
TCMDTactile Systems Technology, Inc.LTM Mar 2026$83.55M +11.1%+4.9%24.3%
KIDSOrthoPediatrics Corp.LTM Mar 2026$65.51M +13.4%+26.3%26.9%
BFLYButterfly Network, Inc.LTM Mar 2026$52.28M +55.2%+15.2%50.8%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$42.05M +1.0%+16.0%20.3%
RXSTRxSight, Inc.LTM Mar 2026$29.3M -43.5%+4.4%23.0%
NPCENeuroPace, Inc.LTM Mar 2026$21.6M +1.8%+20.5%21.7%
DCTHDelcath Systems, Inc.LTM Mar 2026$12.69M +56.1%+158.1%14.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding RXST) $47.16M+13.4%+16.0%24.3%

Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue22.59M49.01M89.08M139.93M134.48M
Cost of Revenue18.08M27.68M35.31M40.98M31.47M
Gross Profit4.52M21.33M53.77M98.94M103.01M
Gross Margin20.0%43.5%60.4%70.7%76.6%
Research & Development24.5M25.98M29.05M34.37M38.55M
Selling, General & Admin32.81M58.67M74.8M101.43M112.65M
Operating Expenses57.3M84.65M103.85M135.8M151.2M
Depreciation & Amortization3.99M4.02M4.24M3.62M0
EBITDA(41.01M)(57.78M)(41.04M)(23.76M)(38.84M)
EBITDA Margin-181.5%-117.9%-46.1%-17.0%-28.9%
Operating Income(52.79M)(63.32M)(50.09M)(36.86M)(48.19M)
Operating Margin-233.6%-129.2%-56.2%-26.3%-35.8%
Interest Income54K1.52M6.57M9.47M2.51M
Interest Expense3.68M4.95M3.31M21K40K
Other Income / Expenses4.11M(3.43M)1.5M9.45M9.31M
Income Before Tax(48.68M)(66.75M)(48.59M)(27.41M)(38.88M)
Pre-Tax Margin-215.5%-136.2%-54.5%-19.6%-28.9%
Income Tax Expense8K9K20K50K66K
Net Income(48.69M)(66.76M)(48.61M)(27.46M)(38.94M)
Net Margin-215.5%-136.2%-54.6%-19.6%-29.0%
EPS (Basic)(1.78)(2.41)(1.41)(0.71)(0.95)
EPS (Diluted)(1.78)(2.41)(1.41)(0.71)(0.95)
Weighted Avg Shares27.37M27.66M34.46M38.87M41.18M
Weighted Avg Shares (Diluted)27.37M27.66M34.46M38.87M41.18M

RxSight, Inc.

NASDAQ:RXST

Intrinsic Alpha fair value

Locked

Current Price

$5.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.